Revolution Medicines' Rasonque placed on China NMPA proposed priority review list for 2L mPDAC

China's NMPA has posted Revolution Medicines' Rasonque (daraxonrasib) on its proposed priority review list for second-line metastatic pancreatic ductal adenocarcinoma (2L mPDAC). Formal inclusion could accelerate the review timeline and support a decision within roughly 130 business days.

Detected & updated continuously · Source: Nebula